Cedra, S.; Wiegand, S.; Kolb, M.; Dietz, A.; Wichmann, G.
Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients. Cancers 2017, 9, 117.
https://doi.org/10.3390/cancers9090117
AMA Style
Cedra S, Wiegand S, Kolb M, Dietz A, Wichmann G.
Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients. Cancers. 2017; 9(9):117.
https://doi.org/10.3390/cancers9090117
Chicago/Turabian Style
Cedra, Susan, Susanne Wiegand, Marlen Kolb, Andreas Dietz, and Gunnar Wichmann.
2017. "Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients" Cancers 9, no. 9: 117.
https://doi.org/10.3390/cancers9090117
APA Style
Cedra, S., Wiegand, S., Kolb, M., Dietz, A., & Wichmann, G.
(2017). Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients. Cancers, 9(9), 117.
https://doi.org/10.3390/cancers9090117